Background: The cesarean delivery rate has been increasing all over the world over the last few years. There is a change in mindset due to the change in women's role, let alone the perception stating that cesarean delivery can decrease the risk of having pelvic floor dysfunction and maintain the sexual functions. Therefore, women think that cesarean delivery is a good choice for delivery, even it has no indications. This study aimed at analyzing and providing quantitative data by comparing the dyspareunia based on FSFI scores between cesarean section and vaginal delivery. Method: The systematic data search was done in the Medical Database (PUBMED, Google Scholar, Cochrane) and the archives of RSUD Dr. Soetomo. The inclusion criteria consisted of (1) observational study with the following keywords ''cesarean section'', ''cesarean delivery '', ''vaginal birth'', ''vaginal delivery'', ''dyspareunia'', ''FSFI'',(2) all included papers could be accessed completely, and the data that had been obtained could be analyzed accurately. Result: Twelve observational studies toward 2144 patients had been analyzed. The dyspareunia score after 3-month of delivery between cesarean section and vaginal delivery had a Mean Difference (MD) of 0.18 and 95% CI of -0.19 to 0.54 (p-value of 0.35). The dyspareunia score after 6-month of delivery between cesarean section and vaginal delivery had a Mean Difference (MD) of 0.43 and 95% CI of -0.28 to 1.14 (p-value of 0.23). Meanwhile, the dyspareunia score after 12-month of delivery between cesarean section and vaginal delivery had a Mean Difference (MD) of 0.12 and 95% CI of -0.23 to 0.48 (p-value of 0.50). From those three forest plots, all diamonds were tangent to the vertical line (no effect) and had a p > 0.05, so it could be inferred that no significant statistical difference was found between the experimental group (cesarean section) and the control group (vaginal delivery). Those three studies were heterogeneous since I 2 was more than 50%. Conclusion: This meta-analysis concludes that there is a tendency for 3-month, 6-month, and 12-month of post delivery dypareunia rate to be lower in cesarean section than vaginal delivery, but it's not staistically significant.
Background : Vulvovaginal atrophy is a condition that often occurs in menopausal women due to Estrogen decreased. Prasterone (DHEA) is a steroid hormone that can be converted into Estrogen in the target tissue. Objective : This paper aims to evaluate the effectiveness of administering Prasterone as Vulvovaginal Atrophy therapy in menopausal women. Methods : A systematic data search was performed on a medical database (PUBMED, Google scholar, Cochrane). Inclusion criteria: (1) randomized study of Prasterone as Vulvovaginal Atrophy therapy in postmenopausal women, (2) all-inclusive papers can be accessed completely, and (3) the data obtained can be accurately analysed. Results: Three RCTs with a total of 696 patients were analysed. The average number of Superficial Cells (mean difference [MD] 7.63, and 95% [CI] 7.57 to 7.70 (P <0.00001). The average number of Parabasal Cells (mean difference [MD] -29.84, and 95% [CI] -30.25 to -29.44 (P <0.00001). The average number of vaginal pH (mean difference [MD] -0.69, and 95% [CI] -0.70 to -0.68 (P <0.00001). The average number of Dyspareunia (mean difference [MD] -0.38, and 95% [CI] -0.39 to -0.37 (P <0.00001). All diamonds do not intersect the vertical line, and have p <0.05, it proves that there are significant differences between the two groups. All non-hysterectomized women have an atrophic or inactive endometrium. Side effects that are often complained of is headache and application site discharge. Conclusion This meta-analysis concludes that Prasterone therapy has a significant therapeutic effect for Vulvovaginal Atrophy in menopausal women
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.